Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From William Looney
ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship
ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope.
In this In Vivo executive roundtable, an informal working group of biopharma leaders in market access reviews the current state of play with regulators, patients and payers. Contacts with the first two stakeholders are clear-eyed and surprisingly productive, but the payer remains the tie that grinds – an inscrutable partner of necessity in moving complex, costly innovations toward acceptance in the marketplace.
In this first installment of VC Playbook, a new series profiling venture capital groups in biopharma and medtech, In Vivo talks to Antoine Papiernik, managing partner and chair of Sofinnova Partners – Europe’s largest and oldest VC devoted to the life sciences, with €2 billion under management.
Now that Project Data Sphere has established itself as a world-class data sharing platform, the group’s leadership is planning for its next phase of the struggle against cancer. Project Data Sphere's president Bill Louv talks to In Vivo about how the group has "raised the bar on what is possible to achieve in cancer research."
The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.
With a challenging new decade of scientific discovery looming, 2019 is the positioning year for biopharma to make value, transparency, information and culture work seamlessly to achieve innovations that matter to patients, payers and society.